human | Q5 |
P269 | IdRef ID | 221095411 |
P244 | Library of Congress authority ID | n2007185345 |
P8189 | National Library of Israel J9U ID | 987007314607305171 |
P496 | ORCID iD | 0000-0001-7502-8049 |
P214 | VIAF ID | 68392136 |
P735 | given name | George | Q15921732 |
George | Q15921732 | ||
P106 | occupation | researcher | Q1650915 |
P21 | sex or gender | male | Q6581097 |
Q57025453 | 1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration |
Q37695414 | 2009 Focused updates to guidelines in ST-elevation myocardial infarction and percutaneous coronary intervention: application to interventional cardiology |
Q91304723 | A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement |
Q51219587 | A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the "crush technique". |
Q43049810 | A risk score to predict bleeding in patients with acute coronary syndromes |
Q28285964 | A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation |
Q46000101 | A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis. |
Q37283092 | ASCERT: the American College of Cardiology Foundation--the Society of Thoracic Surgeons Collaboration on the comparative effectiveness of revascularization strategies |
Q45137335 | Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale |
Q51793900 | Acute and long-term outcomes of cutting balloon angioplasty followed by gamma brachytherapy for in-stent restenosis. |
Q77439600 | Acute angiographic and clinical results of the NIR w/SOX stent |
Q44830908 | Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model |
Q51145784 | American College of Cardiology Annual Scientific Session 2010: update in interventional cardiology. |
Q80257706 | An evaluation of fluoroscopy time and correlation with outcomes after percutaneous coronary intervention |
Q41960243 | Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute ST-segment elevation myocardial infarction: results of the HORIZONS-AMI trial |
Q42792264 | Angiographic complications and post‐PCI myocardial enzyme elevation: Brave new world revisited |
Q46475076 | Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention |
Q40458505 | Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). |
Q31141831 | Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials |
Q83637005 | Angioscopic and virtual histology intravascular ultrasound characteristics of culprit lesion morphology underlying coronary artery thrombosis |
Q37775915 | Antegrade, retrograde, and combination strategies for chronic total occlusions |
Q47204835 | Antithrombotic Treatment after Transcatheter Heart Valves Implant |
Q33446308 | Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry |
Q51170781 | Art and Science of Cerebrovascular Event Prevention After Transcatheter Aortic Valve Replacement. |
Q89423195 | Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention |
Q81514556 | Assessing intermediate left main coronary lesions using intravascular ultrasound |
Q47827567 | Assessment of trans-aortic pressure gradient using a coronary pressure wire in patients with mechanical aortic and mitral valve prostheses. |
Q51831131 | Association among leukocyte count, mortality, and bleeding in patients with non-ST-segment elevation acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] trial). |
Q38639061 | Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study |
Q52373769 | Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. |
Q34974622 | Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial |
Q38460595 | B-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial |
Q41751821 | Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). |
Q90310416 | Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial |
Q46648595 | Bifurcation coronary lesions treated with the "crush" technique: an intravascular ultrasound analysis |
Q33503488 | Bifurcation stenting with drug-eluting stents: a systematic review and meta-analysis of randomised trials. |
Q49958158 | Bioresorbable Vascular Scaffolds in Women |
Q40989593 | Bivalirudin Is Associated With Improved In-Hospital Outcomes Compared With Heparin in Percutaneous Vascular Interventions: Observational, Propensity-Matched Analysis From the Premier Hospital Database |
Q41205746 | Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial |
Q28281179 | Bivalirudin during primary PCI in acute myocardial infarction |
Q33400450 | Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI trial |
Q28256871 | Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial |
Q33428208 | Bivalirudin or Heparin Treatment During Transcatheter Valve Interventions: Where are we Now? |
Q53151867 | Bleeding After Aortic Valve Replacement Matters: Important Mortality Risk. |
Q38380420 | COCATS 4 Task Force 10: Training in Cardiac Catheterization |
Q52984236 | Can Coronary Stent Implantation Complexity Become an Intuitive and Useful Factor to Tailor DAPT Duration? |
Q48099035 | Cardiac enzyme elevation after coronary revascularization. |
Q36983402 | Cardiovascular morbidity and mortality of the metabolic syndrome |
Q96293193 | Cardiovascular outcomes after percutaneous coronary intervention on bifurcation lesions with moderate to severe coronary calcium: A single-center registry study |
Q39438758 | Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). |
Q48720669 | Cerebral Embolism During Transcatheter Aortic Valve Replacement: The BRAVO-3 MRI Study |
Q38413579 | Cerebrovascular events after a primary percutaneous coronary intervention strategy for acute ST-segment-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial |
Q52643133 | Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. |
Q46982016 | Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). |
Q47597302 | Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. |
Q83444440 | Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture |
Q42822404 | Clinical Impact of Enhanced Inhibition of P2Y12-Mediated Platelet Aggregation in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention |
Q35758154 | Clinical Outcome After DK Crush Versus Culotte Stenting of Distal Left Main Bifurcation Lesions: The 3-Year Follow-Up Results of the DKCRUSH-III Study |
Q45916170 | Clinical investigation in ACS and PCI: shooting in the dark at a moving target. |
Q43856223 | Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure |
Q53598043 | Clinical outcome of nonculprit plaque ruptures in patients with acute coronary syndrome in the PROSPECT study. |
Q91747798 | Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial |
Q46834205 | Clinical outcomes after heterogeneous overlap stenting with drug-eluting stents and bare-metal stents for de novo coronary artery narrowings |
Q46523338 | Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial |
Q45227523 | Clinical outcomes in the percutaneous coronary intervention of in-stent restenosis with everolimus-eluting stents. |
Q28302425 | Clinical studies with sirolimus, zotarolimus, everolimus, and biolimus A9 drug-eluting stent systems |
Q45087518 | Clopidogrel loading dose pre-PCI: how high? |
Q89840320 | Combined and independent impact of coronary artery calcification and inflammation on risk for adverse cardiovascular events after percutaneous coronary intervention: Results from a large single-center registry |
Q48937674 | Commentary: New insights into the risk factors of contrast-induced encephalopathy |
Q36351313 | Comparative effectiveness of revascularization strategies |
Q40603186 | Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease |
Q42883088 | Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-corona |
Q60453532 | Comparison of Outcomes of Patients With ST-Segment Elevation Myocardial Infarction With Versus Without Previous Coronary Artery Bypass Grafting (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS- |
Q47432784 | Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial). |
Q82872483 | Comparison of angiographic and intravascular ultrasonic detection of myocardial bridging of the left anterior descending coronary artery |
Q90779682 | Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER-collaboration |
Q56982306 | Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial |
Q44065287 | Comparison of clinical outcomes using stents versus no stents after percutaneous coronary intervention for proximal left anterior descending versus proximal right and left circumflex coronary arteries |
Q79838359 | Comparison of differences in outcome after percutaneous coronary intervention in men versus women <40 years of age |
Q51806173 | Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients ≥75 years of age versus those <75 years of age |
Q75400017 | Comparison of frequency of hemorrhagic stroke in patients <75 years versus > or =75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions |
Q51837478 | Comparison of in-hospital and one-year outcomes after multiple coronary arterial stenting in patients > or =80 years old versus those <80 years old. |
Q43510316 | Comparison of one-year outcomes after percutaneous coronary intervention among current smokers, ex-smokers, and nonsmokers |
Q73246222 | Comparison of outcomes in men versus women having percutaneous coronary interventions in small coronary arteries |
Q51027407 | Comparison of provisional 1-stent and 2-stent strategies in diabetic patients with true bifurcation lesions: the EES bifurcation study. |
Q51638776 | Comparison of safety and efficacy between first and second generation of angio-seal closure devices in interventional patients. |
Q34137536 | Comparison of six risk scores in patients with triple vessel coronary artery disease undergoing PCI: competing factors influence mortality, myocardial infarction, and target lesion revascularization |
Q37019512 | Comparison of surgical pericardial drainage with percutaneous catheter drainage for pericardial effusion |
Q51785128 | Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis. |
Q46873841 | Comparison of the effects of pretreatment with tirofiban, clopidogrel or both on the inhibition of platelet aggregation and activation in patients with acute coronary syndromes |
Q44247305 | Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advanced c-myc antisense at six months follow-up in a rabbit balloon injury model |
Q33924170 | Composite outcomes in coronary bypass surgery versus percutaneous intervention |
Q47673628 | Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: comparison with primary angioplasty and the role of distal protection devices (EMERALD trial). |
Q38215340 | Contemporary overview and clinical perspectives of chronic total occlusions |
Q60453518 | Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy |
Q43064438 | Contrast-induced acute kidney injury. Underappreciated or a new marker of cardiovascular mortality? |
Q45201786 | Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables |
Q44781955 | Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis |
Q41631482 | Coronary Artery Bypass Surgery Compared With Percutaneous Coronary Intervention for Proximal Left Anterior Descending Artery Treatment in Patients With Acute Coronary Syndrome: Analysis From the ACUITY Trial |
Q38886576 | Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. |
Q37459124 | Coronary artery aneurysms after drug-eluting stent implantation |
Q30419699 | Coronary artery calcification is inversely related to body morphology in patients with significant coronary artery disease: a three-dimensional intravascular ultrasound study |
Q28194342 | Coronary artery spasm associated with a moderately severe atherosclerotic stenosis in the proximal LAD |
Q88036703 | Coronary chronic total occlusions: How to dilate the tough ones |
Q51352499 | Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. |
Q39360380 | Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration |
Q73668666 | Correlation of coronary arterial remodeling determined by intravascular ultrasound with angiographic diameter reduction of 20% to 60% |
Q45238081 | Creatine kinase-MB enzyme elevation and long-term clinical events after successful coronary stenting in lesions with ruptured plaque |
Q38890003 | Culprit-lesion only versus complete multivessel percutaneous intervention in ST-elevation myocardial infarction: A systematic review and meta-analysis of randomized trials |
Q38095795 | Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies |
Q47833058 | D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy |
Q51741704 | Dedicated two-stent technique in complex bifurcation percutaneous coronary intervention with use of everolimus-eluting stents: the EES-bifurcation study. |
Q44284349 | Deferoxamine enhances neovascularization and recovery of ischemic skeletal muscle in an experimental sheep model |
Q34740055 | Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial |
Q51749911 | Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. |
Q39515673 | Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes |
Q42332217 | Diabetes mellitus and multivessel coronary artery disease: an ongoing battle for an ideal treatment strategy |
Q42167544 | Dominant contribution of negative remodeling to development of significant coronary bifurcation narrowing |
Q37301358 | Drug-eluting stents in the real world: how intravascular ultrasound can improve clinical outcome |
Q40319620 | Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials |
Q57132788 | Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry) |
Q35963211 | Dual Antiplatelet Therapy Duration: A Review of Current Available Evidence |
Q48356240 | Dual catheter technique for the treatment of severe coronary artery perforations |
Q26852886 | Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials |
Q38392725 | Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials |
Q54141528 | Editorial Comment—Hypotension After Carotid Revascularization |
Q40112204 | Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials |
Q50188567 | Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative |
Q38380117 | Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial |
Q51031387 | Effect of anemia on frequency of short- and long-term clinical events in acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). |
Q40300202 | Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). |
Q44108396 | Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection |
Q93079964 | Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration |
Q84257672 | Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis |
Q48151897 | Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial |
Q46711890 | Effectiveness of drug-eluting stent implantation for patients with unprotected left main coronary artery stenosis |
Q46672411 | Effectiveness of the concomitant use of bivalirudin and drug-eluting stents (from the prospective, multicenter BivAlirudin and Drug-Eluting STents [ADEST] study). |
Q47297262 | Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials |
Q33431313 | Effects of baseline and early acquired thrombocytopaenia on long-term mortality in patients undergoing percutaneous coronary intervention with bivalirudin |
Q39035252 | Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials |
Q38781681 | Efficacy and safety of routine thrombus aspiration in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An updated systematic review and meta-analysis of randomized controlled trials |
Q53208811 | Endovascular treatment of infrarenal aortic stenosis: importance of multimodality imaging. |
Q50725684 | Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents. |
Q38119278 | Evolution of intravascular assessment of coronary anatomy and physiology: from ultrasound imaging to optical and flow assessment |
Q102373871 | Excimer laser coronary atherectomy for uncrossable coronary lesions. A multicenter registry |
Q38037668 | Facilitated/pharmaco-invasive approaches in STEMI. |
Q41069073 | Factors Affecting Bleeding and Stent Thrombosis in Clinical Trials Comparing Bivalirudin With Heparin During Percutaneous Coronary Intervention |
Q51654770 | Favorable effect of gamma-radiation for in-stent restenosis: effect of diabetes on angiographic and clinical outcomes. |
Q51393862 | Female gender and mortality after percutaneous coronary intervention: results from a large registry. |
Q46533338 | First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial |
Q57486604 | Fourth universal definition of myocardial infarction (2018) |
Q45395198 | Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction |
Q51707931 | Gamma radiation for in-stent restenosis: effect of lesion length on angiographic and clinical outcomes. |
Q42634785 | Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial |
Q39438763 | Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes |
Q43957429 | Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors |
Q51305480 | Gender differences in long-term clinical outcomes after percutaneous coronary intervention of chronic total occlusions. |
Q41654886 | Gender-specific outcomes after balloon aortic valvuloplasty: Inhospital and long-term outcomes |
Q46883865 | Gender-specific outcomes after sirolimus-eluting stent implantation |
Q92315017 | Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry |
Q50146799 | Guidelines for Patient-Reported Outcomes in Clinical Trial Protocols |
Q67223888 | Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial |
Q30450312 | High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study |
Q37888541 | How serious a problem is bleeding in patients with acute coronary syndromes? |
Q34943346 | How to diagnose, how to treat: renal artery stenosis-diagnosis and management |
Q33789829 | Humanized mouse model of thrombosis is predictive of the clinical efficacy of antiplatelet agents |
Q40774686 | Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study |
Q40736980 | Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Dr |
Q34486268 | Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis From the HORIZONS-AMI and ACUITY Trials |
Q91748345 | Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents |
Q40319115 | Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention |
Q38378830 | Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention |
Q46262291 | Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). |
Q57412725 | Impact of Major Bleeding on Long-Term Mortality in Anemic Versus Nonanemic Patients Undergoing Percutaneous Coronary Intervention Using Bivalirudin |
Q50662100 | Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibiti |
Q43069516 | Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial). |
Q46368065 | Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions |
Q51783108 | Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials. |
Q33394100 | Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HO |
Q43288786 | Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage str |
Q44994395 | Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention |
Q53597769 | Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials. |
Q44260544 | Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. |
Q54377389 | Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). |
Q85090019 | Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) t |
Q90257344 | Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI |
Q43918642 | Impact of intravascular ultrasound imaging on early and late clinical outcomes following percutaneous coronary intervention with drug-eluting stents |
Q56985462 | Impact of leukocyte count on mortality and bleeding in patients with myocardial infarction undergoing primary percutaneous coronary interventions: analysis from the Harmonizing Outcome with Revascularization and Stent in Acute Myocardial Infarction t |
Q39639977 | Impact of major bleeding and blood transfusions after cardiac surgery: analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial |
Q51758758 | Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. |
Q83795968 | Impact of myocardial bridge on clinical outcome after coronary stent placement |
Q53936363 | Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. |
Q92217180 | Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial |
Q46496318 | Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy). |
Q43709119 | Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus-eluting stents |
Q34060015 | Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data |
Q48158581 | Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial |
Q38938320 | Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry |
Q84817753 | Impact of smoking on outcomes of patients with ST-segment elevation myocardial infarction (from the HORIZONS-AMI Trial) |
Q93141850 | Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: Results from a large single-center registry |
Q75351724 | Impact of symptomatic peripheral arterial disease on 1-year mortality in patients undergoing percutaneous coronary interventions |
Q53364967 | Impact of target vessel on long-term survival after percutaneous coronary intervention for chronic total occlusions. |
Q34021163 | Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials |
Q45982712 | Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. |
Q39278248 | Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial |
Q37812440 | In-stent restenosis in the drug-eluting stent era. |
Q44067510 | Incidence and angiographic characteristics of patients with apical ballooning syndrome (takotsubo/stress cardiomyopathy) in the HORIZONS-AMI trial: an analysis from a multicenter, international study of ST-elevation myocardial infarction |
Q33394098 | Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial |
Q43443221 | Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial |
Q38885545 | Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry |
Q88461145 | Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis |
Q38428199 | Incidence, predictors, and implications of reinfarction after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial |
Q44684605 | Increased CK-MB release is a "trade-off" for optimal stent implantation: an intravascular ultrasound study |
Q91433521 | Influence of Final Kissing Balloon Inflation on Long-term Outcomes After PCI of Distal Left Main Bifurcation Lesions: Analysis From the EXCEL Trial |
Q48096926 | Integrating invasive hemodynamic parameters into risk stratification of acute myocardial infarction and cardiogenic shock |
Q33959229 | Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model |
Q73438377 | Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions |
Q40410810 | Intravascular ultrasonic assessment of stent diameters derived from manufacturer's compliance charts |
Q83297062 | Intravascular ultrasonic differences between aorto-ostial and shaft narrowing in saphenous veins used as aortocoronary bypass grafts |
Q80020261 | Intravascular ultrasound assessment of fibrous cap remnants after coronary plaque rupture |
Q45253566 | Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation |
Q84768530 | Intravascular ultrasound assessment of the incidence and predictors of edge dissections after drug-eluting stent implantation |
Q79279183 | Intravascular ultrasound assessment of ulcerated ruptured plaques: a comparison of culprit and nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes |
Q43144683 | Intravascular ultrasound classification of plaque distribution in left main coronary artery bifurcations: where is the plaque really located? |
Q38490870 | Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) substudy |
Q80960386 | Intravascular ultrasound study of patterns of calcium in ruptured coronary plaques |
Q37122647 | Inverse relationship between body mass index and coronary artery calcification in patients with clinically significant coronary lesions |
Q46000107 | Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chroni |
Q43117188 | Is accurate intravascular ultrasound evaluation of the left circumflex ostium from a left anterior descending to left main pullback possible? |
Q36252020 | Is surgery preferred for the diabetic with multivessel disease? Debate on revascularization strategy for diabetic patients with multivessel coronary artery disease. |
Q48143822 | Ischemia-reperfusion injury and ischemic post-conditioning in acute myocardial infarction: Lost in translation |
Q38023285 | Late stent thrombosis: the last remaining obstacle in coronary interventional therapy |
Q91344896 | Leave nothing behind: Promising results for coronary drug-coated balloons in clinical practice |
Q38443693 | Leukocyte count is a modulating factor for the mortality benefit of bivalirudin in ST-segment-elevation acute myocardial infarction: the HORIZONS-AMI trial |
Q38704416 | Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration |
Q38178840 | Long-term clinical outcomes after percutaneous coronary intervention for chronic total occlusions |
Q46810032 | Long-term clinical outcomes after percutaneous coronary intervention for chronic total occlusions in elderly patients (≥75 years): five-year outcomes from a 1,791 patient multi-national registry |
Q57214404 | Long-term clinical outcomes of percutaneous coronary intervention for chronic total occlusions in patients with versus without diabetes mellitus |
Q73727652 | Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-I, GAMMA-II, and SCRIPPS-III) |
Q84974281 | Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocard |
Q44721871 | Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial |
Q43605422 | Long-term outcome of percutaneous coronary intervention for chronic total occlusions |
Q45240001 | Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions |
Q44252902 | MaXIMAl benefits in the elderly? |
Q57764238 | Management of Patients after Acute Coronary Syndrome |
Q38679410 | Meta-Analysis of Radial Versus Femoral Access for Percutaneous Coronary Interventions in Non-ST-Segment Elevation Acute Coronary Syndrome |
Q53103119 | Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatmen |
Q28191931 | Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting |
Q38373158 | Meta-analysis of trials on mortality after percutaneous coronary intervention compared with medical therapy in patients with stable coronary heart disease and objective evidence of myocardial ischemia |
Q38398190 | Meta-analysis on the impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcome |
Q51689831 | Minimally invasive coronary artery bypass grafting versus stenting for patients with proximal left anterior descending coronary artery disease. |
Q45287676 | Minimally invasive direct coronary artery bypass (MIDCAB) versus coronary artery stenting for elective revascularization of the left anterior descending artery |
Q37188126 | Multivessel disease: percutaneous coronary intervention for classic coronary artery bypass grafting indications |
Q46727655 | Necrotic core and its ratio to dense calcium are predictors of high-risk non-ST-elevation acute coronary syndrome |
Q38986493 | Neurological Outcomes With Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
Q74317542 | New-device angioplasty in women: clinical outcome and predictors in a 7,372-patient registry |
Q50927625 | Nonrandomized comparison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon. |
Q45158732 | Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation |
Q45286576 | Novel site-specific systemic delivery of Rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in a porcine coronary restenosis model |
Q99610712 | One-year clinical outcomes in patients with chronic kidney disease treated with COMBO stents: From the COMBO collaboration |
Q38951997 | One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study |
Q27003223 | Open versus endovascular stent graft repair of abdominal aortic aneurysms: a meta-analysis of randomized trials |
Q51167432 | Open versus endovascular stent graft repair of abdominal aortic aneurysms: do we need more randomized clinical trials? |
Q43585011 | Optimal catchment area and primary PCI centre volume revisited: a single-centre experience in transition from high-volume centre to "mega centre" for patients with ST-segment elevation myocardial infarction |
Q44650101 | Optimal final lumen area and predictors of target lesion revascularization after stent implantation in small coronary arteries |
Q51150191 | Outcome after acute incomplete sirolimus-eluting stent apposition as assessed by serial intravascular ultrasound. |
Q43413010 | Outcome of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention during on- versus off-hours (a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction [HORIZONS- |
Q51498928 | Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. |
Q51373166 | Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [ |
Q89077892 | Overlapping bio-absorbable scaffolds: Aim for D2D technique? |
Q33357497 | PCI options in heparin-induced thrombocytopenia |
Q44546500 | Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction |
Q53311236 | Patients with 3-vessel coronary artery disease and impaired ventricular function undergoing PCI with Impella 2.5 hemodynamic support have improved 90-day outcomes compared to intra-aortic balloon pump: a sub-study of the PROTECT II trial. |
Q90908067 | Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes |
Q38938312 | Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry |
Q52632790 | Percutaneous closure of patent foramen ovale vs. medical treatment for patients with history of cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials. |
Q33361891 | Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopenia |
Q38076852 | Percutaneous recanalization of chronic total occlusions: wherein lies the body of proof? |
Q36282753 | Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. |
Q36288750 | Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. |
Q36254967 | Percutaneous recanalization of chronically occluded coronary arteries: procedural techniques, devices, and results |
Q37909255 | Percutaneous revascularization of left main: role of imaging, techniques, and adjunct pharmacology |
Q53253517 | Performance of currently available risk models in a cohort of mechanically supported high-risk percutaneous coronary intervention--From the PROTECT II randomized trial. |
Q53206956 | Physiological correlates of densely calcified coronary lesions on coronary computed tomography angiography among patients with low-to-intermediate coronary artery disease likelihood. |
Q89125284 | Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study |
Q91635345 | Positioning of self-expanding transcatheter valve prostheses |
Q43897723 | Postprocedure creatine kinase-MB elevation and baseline left ventricular dysfunction predict one-year mortality after percutaneous coronary intervention |
Q39619295 | Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials |
Q34169161 | Prediction of long-term mortality after percutaneous coronary intervention in older adults: results from the National Cardiovascular Data Registry |
Q85209593 | Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial |
Q56983614 | Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial |
Q45100441 | Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). |
Q35954660 | Predictors of long-term survival after coronary artery bypass grafting surgery: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database (the ASCERT study). |
Q38454235 | Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial |
Q35075629 | Premature coronary artery disease in systemic lupus erythematosus with extensive reocclusion following coronary artery bypass surgery |
Q100407259 | Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry |
Q102381687 | Prevalence and prognostic impact of hsCRP elevation are age-dependent in women but not in men undergoing percutaneous coronary intervention |
Q48103275 | Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: Findings from a large multiethnic registry. |
Q50645391 | Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures: Evidence From a Hierarchical Bayesian Network Meta-Analysis of 124 Trials and 28 240 Patients. |
Q83221765 | Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial |
Q84682483 | Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial |
Q80193954 | Prognostic significance of cerebrovascular and peripheral arterial disease in patients having percutaneous coronary interventions |
Q46318609 | Prognostic utility of the SYNTAX score in patients with single versus multivessel disease undergoing percutaneous coronary intervention (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] trial). |
Q38212318 | Prognostic value of access site and nonaccess site bleeding after percutaneous coronary intervention: a cohort study in ST-segment elevation myocardial infarction and comprehensive meta-analysis |
Q54114442 | Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial. |
Q39039443 | Prosthetic Heart Valve Thrombosis |
Q77480632 | Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation |
Q50154495 | Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial |
Q35056263 | Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function |
Q46154973 | Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry |
Q85763381 | Reasonable incomplete revascularisation after percutaneous coronary intervention: the SYNTAX Revascularisation Index |
Q39890592 | Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research |
Q90768291 | Redefining landmarks to improve #safefemoral outcomes |
Q91304729 | Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement |
Q40806431 | Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study |
Q51842734 | Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. |
Q40252817 | Relation of Baseline Hemoglobin Levels and Adverse Events in Patients With Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage strategY and Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardia |
Q51689829 | Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. |
Q85614047 | Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy |
Q83785783 | Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy |
Q44640403 | Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction |
Q50086189 | Reply: Bioresorbable Scaffold Thrombosis: A Multifactorial Phenomenon Also Involving Hypersensitivity Inflammation? |
Q46005634 | Reply: TAVR and Stroke Prevention: Importance of Cerebral Embolic Protection Device Data. |
Q40752196 | Resistant in-stent restenosis in the drug eluting stent era. |
Q44660132 | Restenosis due to underexpansion of sirolimus‐eluting stent in a bifurcation lesion |
Q37615614 | Revascularization for unprotected left main disease: evolution of the evidence basis to redefine treatment standards |
Q38003335 | Revascularization of unprotected left main coronary artery disease: strategy selection and systematic risk assessment |
Q37862838 | Revascularization strategies for stable multivessel and unprotected left main coronary artery disease: from BARI to SYNTAX. |
Q52584692 | Role of Invasive Functional Assessment in Surgical Revascularization of Coronary Artery Disease. |
Q45969326 | Role of PLA2 polymorphism on clinical events after percutaneous coronary intervention. |
Q43268517 | Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial |
Q35863530 | Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions |
Q100757035 | Rolling the rock uphill during left main stenting: The Sisyphus myth in percutaneous coronary intervention? |
Q39764608 | Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials |
Q60453545 | Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction |
Q40812182 | Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis |
Q40126785 | Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis |
Q91756914 | Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention |
Q94678370 | Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY |
Q37760031 | Safety issues related to treating bifurcation lesions. |
Q53544484 | Second-generation drug-eluting stents and bioresorbable vascular scaffolds in patients with diabetes. |
Q90554791 | Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration |
Q50229683 | Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study |
Q39619291 | Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents |
Q39071281 | Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy: TVT Registry From 2011 to 2014. |
Q51121376 | Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: three year results from the HORIZONS-AMI trial. |
Q46834201 | Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era. |
Q51687151 | Short- and long-term results after multivessel stenting in diabetic patients. |
Q39952140 | Significant radiation reduction in interventional fluoroscopy using a novel eye controlled movable region of interest |
Q73438837 | Sirolimus-coated Stent Prevents Neointimal Proliferation |
Q38396170 | Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial |
Q33497692 | Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis |
Q57764282 | Spontaneous coronary artery dissection |
Q44055095 | Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial |
Q38262362 | Stent thrombosis: a clinical perspective |
Q46420633 | Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study |
Q28278561 | Strategies for multivessel revascularization in patients with diabetes |
Q41347812 | Stroke prevention in valvular heart disease: from the procedure to long-term management |
Q56594047 | Subtotal Occlusion of Left Anterior Coronary Artery in a Professional Athlete |
Q51577658 | Successful use of the frontrunner catheter in the treatment of in-stent coronary chronic total occlusions. |
Q38563063 | Surgical Revascularization versus Percutaneous Coronary Intervention and Optimal Medical Therapy in Diabetic Patients with Multi-Vessel Coronary Artery Disease |
Q44776900 | Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model |
Q50976600 | TAVR Through Heavily Calcified Aorta Following Atheroma Retrieval With the "Elevator" Technique. |
Q49391876 | TAVR for Severe Aortic Regurgitation: Advancing the Frontier |
Q91799266 | Temporal trends of survival and utilization of mechanical circulatory support devices in patients with in-hospital cardiac arrest secondary to ventricular tachycardia/ventricular fibrillation |
Q35954502 | The Future REvascularization Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) trial: clinical and angiographic profile at study entry |
Q46514295 | The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale |
Q26741071 | The current role and future prospects of D-dimer biomarker |
Q43833770 | The impact of multivessel disease with and without a co-existing chronic total occlusion on short- and long-term mortality in ST-elevation myocardial infarction patients with and without cardiogenic shock |
Q92679641 | The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial |
Q37830053 | The optimal pharmacological formula for percutaneous coronary intervention |
Q48922947 | The predictive value and evolution of N-terminal pro-B-type natriuretic peptide levels following transcutaneous aortic valve implantation |
Q57796301 | The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry |
Q52596393 | The quest for a "diabetic" stent. |
Q91534770 | The quest for the optimal treatment for in-stent restenosis |
Q35171837 | The relationship among extent of lipid-rich plaque, lesion characteristics, and plaque progression/regression in patients with coronary artery disease: a serial near-infrared spectroscopy and intravascular ultrasound study |
Q43202648 | The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. |
Q38896299 | The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications |
Q37402192 | The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study |
Q47903684 | Thrombo-embolic prevention after transcatheter aortic valve implantation |
Q36419388 | Thrombosis after implantation of drug-eluting stents. |
Q38886590 | Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study |
Q38886583 | Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry |
Q91616328 | Transcatheter Cardiovascular Therapeutics 2018 |
Q90475842 | Transcatheter valve-in-valve for failing bioprosthetic aortic valve: Usually a good idea |
Q91535841 | Transcatheter valves are a viable option for degenerative surgical mitral bioprostheses |
Q93204431 | Transfemoral PCI skill: Use it or lose it.….But #RadialFirst |
Q73250204 | Transplantation of autologous endothelial cells induces angiogenesis |
Q38835461 | Treatment of Higher-Risk Patients With an Indication for Revascularization: Evolution Within the Field of Contemporary Percutaneous Coronary Intervention |
Q51157749 | Treatment of coronary artery perforations complicating percutaneous coronary intervention with a polytetrafluoroethylene-covered stent graft. |
Q46911870 | Treatment of restenotic drug-eluting stents: an intravascular ultrasound analysis. |
Q40454454 | Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. |
Q83078618 | Two-year safety and effectiveness of sirolimus-eluting stents (from a prospective registry) |
Q37465644 | Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis |
Q78772918 | Usefulness of atrial fibrillation as a marker of outcome after percutaneous coronary intervention |
Q47393557 | Usefulness of the angiographic pattern of in-stent restenosis in predicting the success of gamma vascular brachytherapy |
Q50096699 | Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome after drug-eluting stent implantations |
Q47998899 | Valvular Heart Disease in Women, Differential Remodeling, and Response to New Therapies |
Q36131334 | Vascular closure devices: a review of their use after invasive procedures |
Q35885937 | Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis |
Q80845993 | Vascular remodeling and plaque composition between focal and diffuse coronary lesions assessed by intravascular ultrasound |
Q51098019 | Volumetric intravascular ultrasound assessment of neointimal hyperplasia and nonuniform stent strut distribution in sirolimus-eluting stent restenosis. |
Q53353396 | What to do when a patient with coronary stents needs surgery? |
Q50061984 | White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). |
Q91054943 | Why females get better longer-term outcomes with TAVR |
Search more.